Plain-English translation of NCT05686759 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis B research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing I.V.-Hepabig, a hepatitis B prevention medication, in people who have received a liver transplant for hepatitis B-related liver disease. The study compares two ways of giving the medication: undiluted (given quickly over 30 minutes) versus diluted in a glucose solution (given over about an hour). Researchers want to see if the undiluted version works just as well and is as safe as the diluted version.
After a liver transplant for hepatitis B, patients need ongoing medication to prevent the virus from coming back and damaging the new liver. This trial wants to find out if the medication can be given in a simpler, faster way without losing its protective benefits.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through an IV in your arm) either undiluted or diluted, depending on which group you're assigned to. The undiluted version takes about 30 minutes to infuse, while the diluted version takes about an hour. You will have regular screening visits to check your blood work and ensure the medication is working to protect your transplanted liver.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
South Korea